Patient presents with signs and symptoms suggestive of Hepatitis C infection.  Presenting complaints may include fatigue, jaundice, abdominal pain, nausea, and dark urine.  Patient history includes possible risk factors for Hepatitis C Virus (HCV) such as past intravenous drug use, blood transfusion prior to 1992, long-term hemodialysis, occupational exposure to blood, or birth to an HCV-positive mother.  Physical examination may reveal hepatomegaly or splenomegaly.  Initial laboratory testing includes HCV antibody testing.  A positive HCV antibody test indicates past or current HCV infection and necessitates further testing.  HCV RNA testing is performed to confirm active infection.  If HCV RNA is detected, HCV genotype testing is performed to guide treatment decisions.  Liver function tests (LFTs), including ALT, AST, and alkaline phosphatase, are also evaluated to assess liver damage.  Fibrosis assessment is performed using transient elastography or liver biopsy to stage the disease and guide treatment.  Diagnosis of chronic hepatitis C is confirmed by positive HCV RNA and elevated liver enzymes, indicating active viral replication and liver inflammation.  Treatment options for chronic Hepatitis C include direct-acting antiviral agents (DAAs) tailored to the patient's genotype and fibrosis stage.  Treatment goals include achieving sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks after completing treatment, effectively indicating viral eradication.  Patient education regarding transmission prevention, medication adherence, and follow-up care is crucial.  Further monitoring of liver function and HCV RNA levels during and after treatment is necessary to assess treatment response and identify potential complications such as cirrhosis or hepatocellular carcinoma.  ICD-10 codes for Hepatitis C may include B18.2, B17.10, or B19.10, depending on the specific manifestation.  Appropriate CPT codes for diagnostic and treatment procedures will be documented based on services rendered.